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Abstract
AIM
To evaluate the levels of von Willebrand factor (VWF) 
and metalloproteinase with thrombospondin type-1 
motif, number 13 (ADAMTS13) in inflammatory bowel 
disease (IBD) and correlate them with the disease 
activity. 
METHODS
Consecutive patients with IBD aged 18 years or older 
were enrolled in the study. Forty-seven patients with 
ulcerative colitis (UC), 38 with Crohn’s disease (CD), 
and 50 healthy controls were included. The white blood 
cell count, haematocrit, platelet count, fibrinogen, 
partial activated thromboplastin time, C-reactive 
protein, albumin, VWF antigen level (VWF:Ag), VWF 
ristocetin cofactor activity (VWF:RCo), VWF collagen-
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Observational Study
binding activity (VWF:CB), and ADAMTS13 antigen 
level (ADAMTS13:Ag) and activity (ADAMTS13act) 
were measured. The following ratios were assessed: 
VWF:RCo/VWF:Ag, VWF:CB/VWF:Ag, VWF:Ag/
ADAMTS13act, and ADAMTS13act/ADAMTS13:Ag. 
RESULTS
Compared to controls, the odds ratio (OR) of an 
elevated VWF: Ag > 150% was 8.7 (95%CI: 2.7-28.1) 
in the UC group and 16.2 (95%CI: 4.8-54.0) in the CD 
group. VWF:CB was lower in UC patients, and active 
CD was associated with a higher VWF: RCo (+38%). 
The ORs of VWF:CB/VWF:Ag < 0.7 (a marker of 
acquired von Willebrand syndrome) in the UC and CD 
groups were 11.9 (95%CI: 4.4-32.4) and 13.3 (95%CI: 
4.6-38.1), respectively. Active UC was associated 
with lower ADAMTS13:Ag (-23%) and ADAMTS13act 
(-20%) compared to UC in remission. Patients with 
active CD had a 15% lower ADAMTS13act than 
controls. The activity of UC, but not that of CD, was 
inversely correlated with ADAMTS13:Ag (r  = -0.76) and 
ADAMTS13act (r  = -0.81). 
CONCLUSION
Complex VWF-ADAMTS13-mediated mechanisms 
disturb haemostasis in IBD. A reduced WVF:CB is a 
risk factor for bleeding, while a lower ADAMTS13 level 
combined with an elevated VWF:Ag could predispose 
one to thrombosis. 
Key words: ADAMTS13; Inflammatory bowel disease; 
Thrombosis; Acquired von Willebrand syndrome; von 
Willebrand factor
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: A tightly regulated balance between von 
Willebrand factor and metalloproteinase with throm-
bospondin type-1 motif, number 13 (ADAMTS13) is 
important for haemostasis, and its dysregulation might 
predispose one to either thrombotic events or bleeding. 
We demonstrated a decrease in ADAMTS13act levels 
in Crohn’s disease (CD) patients, and in ADAMTS13:
Ag and ADAMTS13act in ulcerative colitis (UC) patients, 
in whom these parameters were negatively correlated 
with disease activity and inflammatory markers. We 
report for the first time the presence of abnormalities 
typical of type A2 acquired von Willebrand syndrome 
in inflammatory bowel disease patients. These findings 
provide insight into the elevated risk for thromboembolic 
events and bleeding observed in UC and less frequently 
in CD.
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INTRODUCTION
In inflammatory bowel disease (IBD), which includes 
ulcerative colitis (UC) and Crohn’s disease (CD), 
a prothrombotic state leads to increased risk for 
thrombosis[1-3]. The estimated risk of venous throm-
boembolism is threefold higher in IBD patients than 
in the general population[4]. A role for microvascular 
thrombi in the pathogenesis of IBD is supported by 
reports of a lower incidence of IBD in patients with 
inherited bleeding disorders, such as haemophilia A and 
B, and von Willebrand’s disease (VWD)[5].
Inflammation and blood coagulation are closely 
related. An inflammatory state disturbs the balance 
between procoagulant and anticoagulant mechanisms, 
leading to enhanced blood coagulation, thrombin 
generation, and deposition of poorly lysable fibrin[6-9]. 
Von Willebrand factor (VWF) is an acute-phase 
protein and a marker of endothelial damage[10-12]. 
Activation of endothelial cells by inflammation impairs 
their anticoagulant function[13-16]. VWF is crucial for 
platelet adhesion and aggregation. High-molecular-
weight multimers (HMWMs) are involved in platelet 
aggregation under high shear stress but present 
solely in the subendothelium and released into the 
bloodstream following activation of endothelial cells 
under normal conditions[17]. 
To assess VWF activity, two assays are commonly 
used: VWF ristocetin co-factor activity (VWF:RCo), 
which evaluates the ability of VWF to interact with 
platelet glycoprotein Ib, and VWF binding to collagen 
(VWF:CB), which evaluates platelet adhesion to collagen 
exposed following damage to the endothelium[18]. 
Type 2A acquired von Willebrand syndrome (AVWS) 
is characterised by an acquired qualitative VWF deficit 
associated with HMWM depletion, which increases the 
risk of mucocutaneous bleeding. VWF:CB is used to 
detect the qualitative abnormalities associated with 
HMWM depletion in type 2A VWD[18]. In the absence 
of shear stress, HMWMs are highly resistant to pro-
teolysis by metalloproteinase with thrombospondin 
type-1 motif, number 13 (ADAMTS13)[19]. Regulation 
of the size of VWF multimers by ADAMTS13 is critical 
for normal haemostasis[20].
ADAMTS13 is a glycoprotein synthesised in endo-
thelial cells and in hepatic stellate cells; it cleaves large 
VWF multimers to smaller, less-active multimers[17]. 
Impaired cleavage of large VWF multimers due 
to inadequate ADAMTS13 levels and/or impaired 
ADAMTS13 activity (ADAMTS13act) leads to thrombotic 
microangiopathies (TMA), which occur in several 
diseases such as thrombotic thrombocytopenic purpura 
(TTP), sepsis, malaria, malignancy, liver diseases, 
myocardial infarction, and ischaemic stroke[11,12,21]. In 
severe inflammatory states, in which the VWF level 
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is markedly elevated, a normal or slightly decreased 
ADAMTS13 level may be insufficient to control ultra-
large VWF (UL-VWF) multimers[22]. 
A tightly regulated balance between VWF and 
ADAMTS13 is important for haemostasis, and its 
dysregulation might predispose one to either throm-
botic events or bleeding. For example, patients 
undergoing elective coronary artery bypass grafting 
with lower preoperative VWF:RCo and high ADAMTS13 
antigen (ADAMTS13:Ag) levels have a higher risk of 
high postoperative bleeding[23].
To the best of our knowledge, the association 
between ADAMTS13:Ag or ADAMTS13act and VWF 
antigen level (VWF:Ag) and activity in IBD has not 
been investigated in connection with the disease clinical 
activity. Therefore, we evaluated the plasma levels of 
these proteins and assessed their associations with 
the clinical characteristics and levels of inflammatory 
markers in patients with IBD. 
MATERIALS AND METHODS
Study population
Consecutive patients with IBD aged 18 years or 
older were enrolled; the study population included 
38 subjects with CD and 47 with UC. Disease was 
diagnosed based on classic histological, endoscopic, 
and radiological criteria[24]. The patients were followed-
up at the Department of Gastroenterology, Hepatology 
and Infectious Diseases, Jagiellonian University 
Medical College, Krakow, Poland. The controls were 
50 healthy volunteers recruited from the hospital 
staff and their acquaintances. The exclusion criteria 
were pregnancy, concomitant inflammatory disorders, 
and severe diseases including myocardial infarction, 
stroke, thromboembolism, known haemorrhagic 
diathesis, cancer, renal insufficiency, liver injury and 
diabetes. None of the patients or volunteers had been 
treated with aspirin, heparin, oral anticoagulants, or oral 
contraceptives. 
The subjects provided informed written consent 
to participate in the study, which was approved by 
the Jagiellonian University Bioethics Committee (no 
KBET/287/B/2014). Participants gave also informed 
consent for data sharing. The study was performed in 
accordance with the ethical principles of the Helsinki 
Declaration of 2008.
Clinical assessment
The clinical assessment included the presence of 
comorbidities, cigarette-smoking habits, and medica-
tions. Body mass index was calculated. In patients 
with CD and UC, the following parameters were 
evaluated: disease duration, disease location, disease 
activity, complications, and past surgical procedures. 
Complications were defined as abscesses, fistulae, and 
stenoses resulting in post-obstructive symptoms. To 
determine the location of lesions in UC and CD patients, 
the Montreal classification was employed[25]. To assess 
CD and UC activity, the CD activity index[26] and disease 
activity index were used[27]. 
Laboratory tests 
Fasting blood samples were collected from the 
antecubital vein in the morning. On the same day, 
using routine laboratory techniques, the following 
laboratory parameters were determined: WBC, haema-
tocrit, platelet count, fibrinogen, partial activated 
thromboplastin time, C-reactive protein (CRP), and 
albumin. 
VWF:Ag was measured by latex immunoassay using 
an STAR coagulation instrument (Diagnostica Stago, 
Asnieres, France), with a detection limit of 2 IU/dL. 
The intra- and inter-assay coefficients of variation were 
5.2% and 5.5%, respectively. VWF:RCo was assessed 
turbidimetrically (Siemens, Erlangen, Germany); the 
intra- and inter-assay coefficients of variation were 
6.9% and 7.5%. The detection threshold for the assay 
was 5 IU/dL. VWF:CB was determined by ELISA using 
type Ⅲ collagen (Sigma) diluted in acetic acid, with 
a limit of detection of 4 IU/dL; the intra- and inter-
assay coefficients of variation were 6.1% and 6.7%. 
ADAMTS13:Ag and ADAMTS13act were quantified 
by means of fluorogenic assays (Technoclone, Wien, 
Austria). The intra- and inter-assay coefficients of 
variation were 5.8% and 6.5% for the level and 7.3% 
and 7.8% for the activity. The lower limit of detection 
of both tests was 5 IU/dL. The normal reference 
ranges for VWF and ADAMTS13 parameters were 
50-150 IU/dL. 
The following ratios were assessed: VWF:RCo/VWF:
Ag, VWF:CB/VWF:Ag, VWF:Ag/ADAMTS13act, and 
ADAMTS13act/ADAMTS13:Ag. 
Statistical analysis
The study was powered to have an 80% likelihood 
of detecting a 30% effect size among patients with 
UC, CD, and healthy controls in ADAMTS13act using 
a significance level α = 0.05 and one-way analysis of 
variance (ANOVA; fixed effects). To demonstrate an 
effect size or greater in this variable, 37 patients were 
required in each group. 
Continuous data with a skewed distribution are 
presented as means with standard deviations or 
medians with interquartile ranges. Discrete data are 
presented as numbers and percentages. To compare 
mean values, a one-way ANOVA was performed if all 
assumptions were met; otherwise a Kruskal-Wallis test 
or Welch test was used. Normality was verified using 
the Shapiro-Wilk test, and the Levene test was applied 
to investigate the heterogeneity of variance. The χ 2 
test or Fisher’s exact test was performed to examine 
associations between categorical data. Odds ratios 
were calculated for selected features. Correlations 
between continuous variables were assessed by calcu-
lating the Pearson or Spearman coefficient. A multivariate 
linear regression was employed to verify the impact of 
factors on ADAMTS13:Ag and ADAMTS13act.
4798 July 14, 2017|Volume 23|Issue 26|WJG|www.wjgnet.com
Cibor D et al . VWF, ADAMTS13 and IBD
4799 July 14, 2017|Volume 23|Issue 26|WJG|www.wjgnet.com
UC (Table 4) and CD (Table 5) as compared to controls. 
VWF activity, as assessed by the VWF:CB coefficient, 
was lower in patients with active and inactive UC 
compared to controls (Table 4). No such difference 
was evident in CD patients (Table 5). Patients with 
active CD had 38% higher VWF: RCo activity than 
the controls (Figure 1). Approximately 50% of the 
IBD patients (n = 42) had a VWF:Ag of greater than 
150%, compared to 8% (n = 4) of the controls. In the 
UC group, the OR of a VWF; Ag greater than 150% 
was 8.7 (95%CI: 2.7-28.1), while in the CD group the 
OR was 16.2 (95%CI: 4.8-54.0) vs controls (Figure 
2). None of the subjects had a deficiency in VWF; no 
cases of VWD were observed.
ADAMTS13 
Patients with active UC had a 23% lower ADAMTS13: 
Ag and ADAMTS13act compared to those in remission 
(Table 4). No such differences were noted in the CD 
group, in which patients with active CD had a 15% 
lower ADAMTS13act than the controls (Table 5). 
Both the UC and CD patients had lower VWF:CB/
VWF:Ag coefficients than the controls. The mean VWF:
CB/VWF:Ag values tended to be lower in patients with 
exacerbated disease compared to subjects in remission 
Calculations were performed using the R statistical 
package version 3.2.2 (The R Foundation for Statistical 
Computing, www.r-project.org). The G*Power 3 
software version 3.1.9.2 was used for the power 
calculation[28]. The statistical review of the study 
was performed by a biomedical statistician, Kinga 
Salapa from the Department of Bioinformatics and 
Telemedicine, Jagiellonian University Medical College.
RESULTS
Patient characteristics
The characteristics of the IBD patients and controls are 
presented in Table 1. Patients with UC were treated 
with mesalamine 2-4 g/d and 10 of them were on 
maintenance therapy with thiopurines. All patients with 
CD were on maintenance therapy with thiopurines and 
the subgroup with inflammatory lesions in the large 
intestine and the ileocecal region was treated with 
mesalamine (2 g/d). Data for the active and inactive 
UC and CD groups are presented in Tables 2 and 3, 
respectively.
VWF 
VWF:Ag was higher in patients with active and inactive 
Ulcerative colitis Crohn’s disease Control group
n  = 47 n  = 38 n  = 50
Men     22 (46.81)      20 (52.63) 35 (70)
Age, yr      37 (26-47)b     29.5 (22-34) a      36 (29-46)
BMI, kg/m2     22.1 (20.5-25)         20.43 (18.38-22.9)         23.9 (22.2-25.3)
Smoking      9 (19.15)      15 (39.47) 17 (34)
Disease duration, yr      5 (2.5-9) 3.5 (2-6) NA
Surgery 0 (0)b    11 (28.9) NA
Complications    3 (6.4)b    11 (28.9) NA
Location
Rectum     7 (14.9) NA NA
Left-sided   25 (53.2) NA NA
Extensive colitis   15 (31.9) NA NA
Ileal NA    12 (31.6) NA
Colonic NA    3 (7.9) NA
Ileocolonic NA    23 (60.5) NA
Pregnancies, n 17 12 13
Miscarriages, n   0   1   1
Table 1  Characteristics of the studied subjects  n  (%)
aP < 0.05 vs the control group, bP < 0.05 vs the Crohn’s disease group. BMI: Body mass index.
Ulcerative colitis inactive Ulcerative colitis active Control group
n  = 21 n  = 26 n  = 50
Disease activity index (points)  2.33 ± 1.68b  7.96 ± 1.91 NA
White blood cells, × 103/µL     6.89 (4.91-7.74)    8.22 (5.54-9.65) 6.75 (6.1-7.9)
Platelet coun, × 103/µL 286.02 (216-303) b     326 (252-379) a 229.5 (199-268)
Haematocrit (%)           43.4 (39.95-44.55) b  39.85 (36.8-42.2)  41.1 (39.5-43)
Haemoglobin, g/dL 13.5 ± 1.67 12.7 ± 1.5a 14.3 ± 1.1
Fibrinogen, g/L       2.52 (2.19-3.92) b      4.97 (3.83-6.99) a     3.05 (2.48-4.16)
CRP, mg/L       1.24 (0.79-1.89) b      10.7 (7.22-20.8) a   1.68 (.98-2.24)
Table 2  Comparison of active and inactive ulcerative colitis groups and controls
aP < 0.05 vs the control group, bP < 0.05 vs active ulcerative colitis group. CRP: C-reactive protein.
Cibor D et al . VWF, ADAMTS13 and IBD
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(P > 0.05). Importantly, the OR of a VWF:CB/VWF:
Ag < 0.7 in the UC group was 11.9 (95%CI: 4.4-32.4) 
vs controls, while that in the CD patients was 13.3 
(95%CI: 4.6-38.1). The OR of a VWF:RCo/VWF:Ag 
of less than 0.7 in the UC group was 18.7 (95%CI: 
1.0-337.4) and that in the CD group was 20.2 (95%CI: 
1.1-370.8) vs control subjects. 
The VWF:Ag/ADAMTS13act coefficients were 
higher in the two disease groups than in the control 
group. In the UC group, there were inverse correlations 
between ADAMTS13: Ag and VWF:RCo (r = -0.35, P 
= 0.0168) and between ADAMTS13:Ag and VWF:Ag 
(r = -0.33, P = 0.0245). In the CD group there were 
inverse associations between ADAMTS13:Ag and VWF:
Ag (r = -0.39, P = 0.0158) and between ADAMTS13:
Ag and VWF:CB (r = - 0.33, P = 0.0388). In both 
groups, ADAMTS13:Ag was closely correlated with 
ADAMTS13act (UC: r = 0.98; CD: r = 0.85; P < 0.0001 
for both). 
VWF:CB was negatively correlated with disease 
activity (r = -0.35, P = 0.0157) and positively correlated 
with disease duration (r = 0.38, P = 0.0116) in the UC 
group. UC patients also showed inverse correlations 
between disease activity and ADAMTS13: Ag (r = 
-0.76, P < 0.0001) and ADAMTS13act (r = -0.81, P < 
0.0001) (Figure 3). 
The multivariate linear regression model showed 
that in the UC patients 63.5% of the ADAMTS13Ag 
variation was associated with three predictors: disease 
activity, CRP, and platelets, with the first having the 
greatest effect (Table 6). Moreover, disease activity 
explained approximately 61.4% of the variation in 
Crohn’s disease inactive Crohn’s disease active Control group
n  = 16 n  = 22 n  = 50
CDAI (points)   83.38 ± 33.30b 236.05 ± 63.46 NA
White blood cells, × 103/µL    6.74 (5.47-7.08)    6.71 (4.91-9.02) 6.75 (6.1-7.9)
Platelet count, × 103/µL 291.5 (209-336)b 324.5 (289-386)a 229.5 (199-268)
Haematocrit, %       42.7 (39.75-45.1)b     37.9 (35.8-39.8)a  41.1 (39.5-43)
Haemoglobin, g/dL 13.99 ± 1.36b 12.15 ± 1.4a 14.3 ± 1.1
Fibrinogen, g/L   3.81 (2.63-4.7)b     6.52 (4.76-8.26)a     3.05 (2.48-4.16)
CRP, mg/L     2.95 (1.19-5.72)b     33.8 (16.4-72.3)a     1.68 (0.98-2.24)
Table 3  Comparison of active and inactive Crohn’s disease groups and controls
aP < 0.05 vs the control group, bP < 0.05 vs active Crohn’s disease group. CDAI: Crohn’s disease activity index; CRP: C-reactive protein.
Ulcerative colitis inactive Ulcerative colitis active Control group
n  = 21 n  = 26 n  = 50
VWF:RCo, IU/dL 120.61 ± 36.33 134.2 ± 46.7 114.03 ± 24.67
VWF:Ag, IU/dL         139.6 (110.3-166.5)a    144.95 (120.8-180.5)a   106.65 (90.7-122.5)
VWF:CB, IU/dL    84.93 ± 13.88a    78.87 ± 14.99a 97.99 ± 10.3
ADAMTS13: Ag (IU/dL)      86.15 ± 10.17a,b    66.39 ± 11.45a 103.86 ± 10.84
ADAMTS13act (IU/dL)       81.2 (79.4-92.9)b   65.05 (55.7-75.1) a     111.0 (97.8-122.8)
VWF:RCo/VWF:Ag      0.96 (0.92-0.97)   0.97 (0.87-1.01)     0.97 (0.91-1.15)
VWF:CB/VWF:Ag        0.68 (0.50-0.79)a       0.5 (0.45-0.70) a     0.91 (0.80-1.05)
VWF:Ag/ADAMTS13act        1.54 (1.34-2.07)a     2.22 (1.65-2.84) a     0.98 (0.79-1.20)
ADAMTS13act/ADAMTS13:Ag       1.01 (0.97-1.02)     1.0 (0.97-1.03)     1.02 (0.94-1.18)
Table 4  Characteristics of markers in active and inactive ulcerative colitis groups and controls
aP < 0.05 vs the control group, bP < 0.05 vs active ulcerative colitis group.
Crohn’s disease inactive Crohn’s disease active Control group
n  = 16 n  = 22 n  = 50
VWF:RCo, IU/dL   143.47 ± 46.12 157.04 ± 61.03a 114.03 ± 24.67
VWF:Ag, IU/dL          135.4 (116.85-175.65)a  182.98 (130.4-219.8)a 106.65 (90.7-122.5)
VWF:CB, IU/dL      98.85 (86.15-102.25) 89.3 (80.6-99.7)   98.05 (91.9-101.8)
ADAMTS13:Ag, IU/dL 104.44 ± 9.96  99.29 ± 15.33 103.86 ± 10.84
ADAMTS13act, IU/dL 104.82 ± 8.61   94.48 ± 15.74a 111.05 ± 17.69
VWFRCo/VWF:Ag   0.96 (0.95-1.00) 0.96 (0.79-1.01)   0.97 (0.91-1.15)
VWF:CB/VWF:Ag    0.65 (0.45-0.87)a  0.54 (0.45-0.65)a   0.91 (0.80-1.05)
VWF:Ag/ADAMTS13act    1.26 (1.12-1.62)a  1.88 (1.48-2.56)a   0.98 (0.79-1.20)
ADAMTS13act/ADAMTS13:Ag   0.99 (0.94-1.05) 0.96 (0.92-1.03)   1.02 (0.94-1.18)
Table 5  Characteristics of markers in active and inactive Crohn’s disease groups and controls
aP < 0.05 vs the control group.
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ADAMTS13act in UC patients. 
In the UC group, ADAMTS13: Ag was inversely 
correlated with platelet counts (r = - 0.57, P < 0.0001), 
fibrinogen (r = -0.62, P < 0.0001), and CRP levels 
(r =-0.67, P < 0.0001). Similar associations were 
observed for ADAMTS13act in this group (r = -0.55, r 
= -0.7, and r = -0.72, all P < 0.0001, respectively). 
In the CD group, there were no associations 
between ADAMTS13:Ag and inflammatory markers. 
However, ADAMTS13act was inversely correlated with 
fibrinogen (r = -0.36, P = 0.0286) and CRP (r = -0.45, 
P = 0.0048). 
DISCUSSION
This is the first report of the effects of novel para-
meters associated with the structure and function 
of VWF on haemostasis in IBD. On the one hand, 
ADAMTS13:Ag was lower in IBD patients than in 
controls, particularly in subjects with UC; this resulted 
in an increased number of circulating multimers 
of VWF and thus an elevated thrombotic risk. The 
prothrombotic effects are enhanced by markedly 
elevated VWF:Ag. On the other hand, the incidence of 
AVWS, which leads to increased risk for bleeding, was 
higher in IBD patients. These findings provide insight 
into the elevated risk for thromboembolic events and 
bleeding observed in UC and less frequently in CD. The 
dysregulation of the balance between VWF function 
and ADAMTS13 reported herein might contribute to 
the complex haemostatic abnormalities observed in 
IBD.
Data on VWF and ADAMTS13 in IBD are scarce. 
Feys et al[29] reported no differences in VWF:Ag, 
ADAMTS13:Ag, and ADAMTS13act between UC 
and CD patients compared to healthy controls; the 
ADAMTS13:Ag was lower only in those with a CRP > 
10 mg/L. However, that study included only 27 patients 
with CD and 17 with UC. Moreover, the ADAMTS13act/
ADAMTS13:Ag ratio exhibited no intergroup differences. 
Similarly, we did not find any differences in the 
ADAMTS13act/ADAMTS13:Ag coefficient between our 
IBD and control groups. Lack of these differences may 
point to the quantitative nature of the defect[30].
A congenital or acquired deficit in ADAMTS13 has 
been reported in numerous diseases accompanied 
by TMA (e.g., TTP, ischaemic stroke). For example, 
Klonizakis et al[31] reported that ADAMTS13 is a 
prognostic marker of microthrombotic manifestations 
in systemic lupus erythematosus. Other authors 
have demonstrated that the levels of ADAMTS13:
Ag and ADAMTS13act in disseminated intravascular 
coagulation are associated with disease severity and 
mortality[32]. Enooku et al[33] showed in a Japanese 
population that the ADAMTS13 concentration was 
negatively correlated with the levels of inflammatory 
markers, arterial pressure, and pulse pressure. 
ADAMTS13 plays a role in inflammatory processes, 
oxidative stress, and atherosclerosis[33,34]. A reduction 
in ADAMTS13act and increases in VWF:Ag may 
increase risk for ischaemic stroke, cerebral infarction, 
and myocardial infarction[35,36]. In patients with 
infectious and noninfectious systemic inflammatory 
response syndrome, ADAMTS13 levels are negatively 
correlated with platelet count[12]. Such an association 
in UC patients is our novel finding. 
It is possible that during inflammation, there is an 
increase in the number of large VWF multimers and 
a decrease in the level and activity of ADAMTS13:Ag, 
while the degree of disturbance in the balance of these 
markers is related to the severity of inflammation 
and the degree of organ failure[16,21]. An acquired de-
crease in ADAMTS13 level can be caused by several 
mechanisms[33]. These include excessive consumption 
ADAMTS13:Ag ADAMTS13act
Platelets β = -0.03 (95%CI: -0.07; -0.01) -
P = 0.044
C-reactive protein β = -0.19 (95%CI: -0.33; -0.05)   β = -0.25 (95%CI: -0.38; -0.12)
P = 0.103 P < 0.001
Disease activity β = -2.27 (95%CI: -3.18; -1.35) β = -0.2.27 (95%CI: -3.48; -1.86)
P < 0.001 P < 0.001
adj.R2 65.3% 69.5%
Table 6  Results of multiple linear regression in ulcerative colitis patients
Results show the estimated value of parameter, P-value for the t-test and adjusted determinant coefficient. Additional, 95%CI of parameter’s estimate when 
P < 0.05. adj.R2: Adjusted determinant coefficient.
a
180
160
140
120
IU
/d
L
CD non-active                  CD active                     Controls
Figure 1  Activity of vWF: RCo in the Crohn’s disease group and the 
controls. CD: Crohn’s disease.
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of ADAMTS13 due to increased HMWM release from 
activated endothelium. ADAMTS13 becomes inactive 
after cleaving its substrate[37]. In addition, inhibition 
of ADAMTS13 synthesis by proinflammatory cyto-
kines (interleukin 6 or TNF-alpha), or inactivation 
of ADAMTS13 by proteases released from neutro-
phils during inflammation occur in inflammatory dis-
eases[38,39]. Interleukin 6 also has the ability to degrade 
ADAMTS13[21]. ADAMTS13 activity may be regulated by 
coagulation proteinases; thrombin, plasmin, and factor 
Xa activity may lead to inactivation of ADAMTS13[38,39]. 
Based on a mouse model, Chauchan et al[40] sug-
VWF:RCo/VWF:Ag VWF:Ag VWF:CB/VWF:Ag
< 0.7                      > 0.7 < 150%                   > 150% < 0.7                      > 0.7
UC
CD
CON
7
14.9%
40
85.1%
6
15.8%
32
84.2%
50
100%
27
57.4%
20
42.8%
16
42.1%
22
57.9%
46
92%
4
8%
31
68%
16
34%
26
68.4%
12
31.6%
7
14%
43
86%
Figure 2  Occurrence of vWF:Ag > 150%, vWF:RCo/vWF: Ag < 0.7 and vWF: CB/vWF:Ag < 0.7 in patients with ulcerative colitis, Crohn’s disease and in the 
control group. 
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Figure 3 Correlation between selected haemostatic parameters and disease activity, and its duration. A: Correlation between disease duration and vWF: CB in 
patients with UC; B: Correlation between disease activity and vWF: CB in patients with ulcerative colitis (UC); C: Correlation between disease activity and ADAMTS13:
Ag in patients with UC. D: Correlation between disease activity and ADAMTS13act in patients with UC.
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gested that by cleaving UL-VWF multimers, ADAMTS13 
downregulates inflammation, while its deficit leads to 
increased leukocyte adhesion in vessels with inflam-
matory lesions, as well as increased extravasation 
of leukocytes. The diversity of mechanisms affecting 
the level and activity of ADAMTS13 confirms the inter-
dependence of inflammation and coagulation.
A decrease in ADAMTS13act in association with an 
increase in the VWF:Ag/ADAMTS13act coefficient may 
be a risk factor for thrombosis and coagulopathy[41]. 
Claus et al[21] reported that significant disturbances 
in the balance between VWF:Ag and ADAMTS13act 
can result in the formation of UL-VWF multimers. The 
authors proposed that the VWF:Ag/ADAMTS13act 
ratio should be defined as the TMA index. High TMA 
index values in patients with inflammation and sepsis 
suggest that the index may be employed to diagnose 
highly prothrombotic states, and that its diagnostic 
value may be higher than that of VWF multimers 
alone[21]. In vitro studies have demonstrated a correla-
tion between the presence of UL-VWF multimers and 
VWF:RCo[42].
Administration of recombinant ADAMTS13 in a 
mouse model of acquired TTP prevents development 
of symptoms; in contrast, in a mouse model of cerebral 
ischaemia it decreases the extent of stroke and 
improves the functional state[43,44]. Straat et al[45] 
showed that administration of frozen fresh plasma 
improved endothelial damage and inflammatory para-
meters, which was related to an increase in ADAMTS13 
levels. Therefore, ADAMTS13 may be a new, alternate 
therapeutic agent for diseases involving disturbances of 
the balance between VWF and ADAMTS13. 
We showed that the VWF:Ag/ADAMTS13act ratio 
was higher in patients with UC and CD compared to 
controls. These results confirm that hypercoagulability 
occurs in IBD, to which VWF is an important contributor. 
Notably, in approximately 50% of IBD patients, the 
VWF:Ag value was greater than 150%, compared to 
8% in the controls. The inflammatory nature of IBD is 
associated with increased levels of VWF:Ag, which our 
findings support.
In contrast, the VWF:CB level in the present study 
was lower in the UC group than the control and CD 
groups. This suggests reduced collagen binding by 
VWF, leading to impaired platelet adhesion to damaged 
endothelium, as collagen itself has limited platelet-
binding ability[13]. Clinically, this may manifest as gas-
trointestinal bleeding, which is more common in UC 
patients.
 The VWF:CB/VWF:Ag ratio was lower in the UC 
and CD groups than the control group, and the OR of 
a VWF:CB/VWF:Ag ratio lower than 0.7 was 12- and 
13-fold higher in the UC and CD groups, respectively. 
The VWF:RCo/VWF:Ag ratio did not differ among the 
CD, UC, and control groups; however, the IBD group 
included patients with a VWF:RCo/VWF:Ag coefficient 
below 0.7, while the control group did not. 
VWF:RCo/VWF:Ag and VWF:CB/VWF:Ag coefficients 
of less than 0.7 are seen in patients with type 2A VWD, 
indicating substantial depletion of HMWM[45]. Riddell 
et al[18] reported that VWF:CB assessment is a more 
sensitive method for diagnostic management of type 
2A VWD. Thus, the findings of our study suggest 
that the risk for AVWS in IBD patients is almost 
20-fold higher than that in healthy individuals. This 
is of practical importance, for example, in patients 
undergoing antithrombotic prophylaxis during periods 
of IBD exacerbation, as it enables the identification of 
patients at increased risk for gastrointestinal bleeding. 
This study had several limitations. First, the 
groups contained relatively few patients. Second, the 
presence of large VWF multimers in plasma was not 
analysed. Associations do not necessarily indicate 
a causal relationship; therefore, in vitro and animal 
model studies are necessary to elucidate the molecular 
mechanisms underlying our findings. Finally, this was 
a case-control study and patients were not followed in 
terms of thromboembolic events or the duration and 
severity of bleeding. 
To our knowledge, the present study is the first 
to demonstrate a decrease in ADAMTS13act levels in 
CD patients, and in ADAMTS13:Ag and ADAMTS13act 
in UC patients, in whom these parameters were 
negatively correlated with disease activity and the levels 
of inflammatory markers. ADAMTS13:Ag represents 
a link between blood coagulation and inflammation 
in IBD. ADAMTS13:Ag deficit in IBD is quantitative 
by nature, possibly due to increased proteolysis of 
large VWF multimers. The elevated TMA index in IBD 
patients indicates increased risk for thromboembolic 
complications. In this group, the use of anticoagulation 
prophylaxis might be considered during disease flares 
not only in patients being hospitalised. 
We also report for the first time the presence of 
abnormalities typical of type 2A AVWS in IBD patients. 
Determination of the VWF:Ag concentration and VWF 
activity may facilitate the identification of IBD patients 
at risk for bleeding complications and the management 
of patients with exacerbated disease, particularly 
when anticoagulation prophylaxis is recommended. 
In this group, a specific for AVWS treatment might be 
implemented during invasive procedures, especially 
surgery. Further studies involving larger patient 
populations and long-term follow-up are needed to 
validate our finding of a role for VWF in IBD.
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microangiopathies. In severe inflammatory states, in which the VWF level is 
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insufficient to control ultra-large VWF multimers. 
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Research frontiers
Inflammatory bowel disease (IBD) patients are at threefold higher risk for 
thromboembolic complications than the general population. This risk is 
especially high during hospitalizations, surgery or active disease and results 
from various hereditary and acquired factors. 
Innovations and breakthroughs
This study demonstrated a decrease in ADAMTS13 activity levels in Crohn’s disease 
patients and in ADAMTS13 antigen and ADAMTS13 activity in ulcerative colitis 
patients, in whom these parameters were negatively correlated with disease 
activity and inflammatory markers. On the other hand, the study showed for 
the first time the presence of abnormalities typical of type A2 acquired von 
Willebrand syndrome in IBD patients.
Applications
If further studies confirm the clinical relevance of these results, they may 
facilitate the individualization of antithrombotic therapy in patients with IBD. 
The elevated VWF antigen/ADAMTS13 activity ratio indicates an increased 
risk for thromboembolic complications. In this group, the use of anticoagulation 
prophylaxis might be considered not only in patients undergoing surgery 
or hospitalizations due to disease flare-ups but also in outpatients with 
disease exacerbation. On the other hand, determination of the VWF antigen 
concentration and VWF activity may facilitate the identification of IBD patients 
at higher risk for bleeding complications and the management of patients 
with exacerbated disease, particularly when anticoagulation prophylaxis is 
recommended. In this group, a specific for acquired von Willebrand syndrome 
treatment might be implemented during invasive procedures, especially surgery.
Terminology
VWF is an acute-phase protein and a marker of endothelial damage. Its function 
is crucial for platelet adhesion and aggregation. ADAMTS13 is a glycoprotein 
that cleaves large VWF multimers to smaller, less-active multimers. Type 2A 
acquired von Willebrand syndrome is characterised by an acquired qualitative 
VWF deficit associated with high-molecular-weight multimers depletion, which 
increases the risk of mucocutaneous bleeding.
Peer-review
The manuscript Levels and activities of von Willebrand factor and metallo-
proteinase with thrombospondin type-1 motif, number 13 in IBD is an interesting 
original research with clear objectives. 
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